BiotechTube

Ioversol 320 mgI/mL + Iodixanol 320 mgI/mL

ApprovedTerminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Renal Impairment

Conditions

Renal Impairment

Trial Timeline

Jan 1, 2009 → Jun 1, 2009

NCT ID
NCT00793182

About Ioversol 320 mgI/mL + Iodixanol 320 mgI/mL

Ioversol 320 mgI/mL + Iodixanol 320 mgI/mL is a approved stage product being developed by Guerbet for Renal Impairment. The current trial status is terminated. This product is registered under clinical trial identifier NCT00793182. Target conditions include Renal Impairment.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00793182ApprovedTerminated

Competing Products

20 competing products in Renal Impairment

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23

Other Products from Guerbet

DOTAREMApproved
77
Dotarem®-enhanced MRIApproved
77
Xenetix + VisipaqueApproved
77
Dotarem + GadovistApproved
77
Gadoterate meglumine + GadobutrolApproved
77